title: Eluxadoline: First Global Approval.
abstract: Eluxadoline (Viberzi(™)), developed by Actavis (now Allergan), is an orally administered, first-in-class compound that functions as both a µ-opioid receptor agonist and a δ-opioid receptor antagonist, and is indicated for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D) in adults. The agent was originally developed by Janssen Pharmaceutica. Eluxadoline has been approved in the US, and submissions to other global authorities are being contemplated or planned. This article summarizes the milestones in the development of eluxadoline leading to this first approval for IBS-D.
authors.affiliation: Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand, dru@adis.com.
authors.forename: Karly P
authors.initials: KP
authors.lastname: Garnock-Jones
mesh_terms: D000328:Adult; D000818:Animals; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology; D017277:Drug Approval; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017465:Receptors, Opioid, delta / Q000037:antagonists & inhibitors; D017450:Receptors, Opioid, mu / Q000819:agonists
chemical_list: D005765:Gastrointestinal Agents; D007093:Imidazoles; D017465:Receptors, Opioid, delta; D017450:Receptors, Opioid, mu; C583636:eluxadoline; D010649:Phenylalanine